Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6299]

Nuclear receptors as targets in brain cancer therapy

Nuclear receptors as targets in brain cancer therapy

WCLC 2025: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC

WCLC 2025: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC

WCLC 2025: Continuing osimertinib treatment through progression with the addition of chemo improves progression-free survival in EGFR-mutated NSCLC

WCLC 2025: Continuing osimertinib treatment through progression with the addition of chemo improves progression...

WCLC 2025: Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

WCLC 2025: Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study...

New radiotheranostic targets identified for diagnosis and treatment of endometrial cancer

New radiotheranostic targets identified for diagnosis and treatment of endometrial cancer

New multi-omics study uncovers key RNA-driven network behind colorectal cancer progression and immune resistance

New multi-omics study uncovers key RNA-driven network behind colorectal cancer progression and immune resistance

Study identifies key features of cancer cell response and resistance to treatment

Study identifies key features of cancer cell response and resistance to treatment

Immune cell therapy for advanced head and neck cancer helps stabilise disease

Immune cell therapy for advanced head and neck cancer helps stabilise disease

Why breast cancer therapy tamoxifen may lead to higher risk of uterine cancer

Why breast cancer therapy tamoxifen may lead to higher risk of uterine cancer

Epstein-Barr virus protein EBNA1 upregulates oncogenes in cervical cancer cells

Epstein-Barr virus protein EBNA1 upregulates oncogenes in cervical cancer cells

More from ecancer